Intractable Diabetic Ketoacidosis with Enfortumab Vedotin

被引：1
|
作者：
Elahi, Amna
Duron, Javier
Porter, Tama
机构：
来源：
DIABETES | 2023年 / 72卷
关键词：
D O I：
10.2337/db23-1851-PUB
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1851-PUB
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Enfortumab Vedotin and Pembrolizumab - A New Perspective on Urothelial Cancer
    Niegisch, Guenter
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (10): : 944 - 946
  • [32] Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
    Powles, T.
    Valderrama, B. P.
    Gupta, S.
    Bedke, J.
    Kikuchi, E.
    Hoffman-Censits, J.
    Iyer, G.
    Vulsteke, C.
    Park, S. H.
    Shin, S. J.
    Castellano, D.
    Fornarini, G.
    Li, J. R.
    Guemues, M.
    Mar, N.
    Loriot, Y.
    Flechon, A.
    Duran, I
    Drakaki, A.
    Narayanan, S.
    Yu, X.
    Gorla, S.
    Moreno, B. Homet
    van der Heijden, M. S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (10): : 875 - 888
  • [33] Enfortumab-vedotin/pembrolizumabLack of efficacy: case report
    Reactions Weekly, 2025, 2055 (1) : 141 - 141
  • [34] Enfortumab-vedotin/InsulinRefractory hyperglycaemia and lack of efficacy
    Reactions Weekly, 2024, 1992 (1) : 86 - 86
  • [35] Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date
    Moussa, Mohamad
    Papatsoris, Athanasios
    Abou Chakra, Mohamed
    Dellis, Athanasios
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2021, 15 : 453 - 462
  • [36] Enfortumab vedotin/insulinVarious toxicities and lack of efficacy: case report
    Reactions Weekly, 2022, 1891 (1) : 134 - 134
  • [37] Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin
    Fahey, Catherine C.
    Nebhan, Caroline A.
    York, Sally
    Davis, Nancy B.
    Hurley, Paula J.
    Gordetsky, Jennifer B.
    Schaffer, Kerry R.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (22)
  • [38] Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
    Catalano, Martina
    Santoni, Matteo
    Roviello, Giandomenico
    EUROPEAN UROLOGY, 2024, 86 (03) : 283 - 283
  • [39] Enfortumab-vedotin/PembrolizumabDermatitis and pneumonitis: 2 case reports
    Reactions Weekly, 2024, 2026 (1) : 128 - 128
  • [40] EXPERT COMMENTARY ON THE PRODUCT PROFILE OF Enfortumab Vedotin Plus Pembrolizumab
    Hanna, Kirollos S.
    ONCOLOGY-NEW YORK, 2024, 38 (05):
12345